RhumbLine Advisers’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $16.3M | Sell |
187,772
-2,926
| -2% | -$177K | 0.01% | 858 |
|
|
2026
Q1 | $7.69M | Buy |
190,698
+4,010
| +2% | +$150K | 0.01% | 1193 |
|
|
2025
Q4 | $6.5M | Sell |
186,688
-1,530
| -0.8% | -$120K | 0.01% | 1259 |
|
|
2025
Q3 | $15.6M | Buy |
188,218
+1,747
| +0.9% | +$126K | 0.01% | 869 |
|
|
2025
Q2 | $13.7M | Sell |
186,471
-14,930
| -7% | -$1.08M | 0.01% | 916 |
|
|
2025
Q1 | $23M | Buy |
201,401
+565
| +0.3% | +$34.4K | 0.02% | 620 |
|
|
2024
Q4 | $10.1M | Sell |
200,836
-1,996
| -1% | -$105K | 0.01% | 1051 |
|
|
2024
Q3 | $9.39M | Buy |
202,832
+44
| +0% | +$1.56K | 0.01% | 1096 |
|
|
2024
Q2 | $6.59M | Sell |
202,788
-3,956
| -2% | -$108K | 0.01% | 1242 |
|
|
2024
Q1 | $5.21M | Sell |
206,744
-5,549
| -3% | -$131K | 0.01% | 1400 |
|
|
2023
Q4 | $6.9M | Buy |
212,293
+7,035
| +3% | +$193K | 0.01% | 1232 |
|
|
2023
Q3 | $5.59M | Buy |
205,258
+454
| +0.2% | +$13.1K | 0.01% | 1276 |
|
|
2023
Q2 | $4.56M | Sell |
204,804
-5,980
| -3% | -$138K | 0.01% | 1432 |
|
|
2023
Q1 | $4.57M | Buy |
210,784
+12,976
| +7% | +$284K | 0.01% | 1381 |
|
|
2022
Q4 | $4.02M | Buy |
197,808
+1,054
| +0.5% | +$26.4K | 0.01% | 1404 |
|
|
2022
Q3 | $5.04M | Buy |
196,754
+9,881
| +5% | +$264K | 0.01% | 1220 |
|
|
2022
Q2 | $4.44M | Buy |
186,873
+5,417
| +3% | +$118K | 0.01% | 1303 |
|
|
2022
Q1 | $4.09M | Buy |
181,456
+2,895
| +2% | +$61.6K | 0.01% | 1442 |
|
|
2021
Q4 | $3.54M | Sell |
178,561
-1,064
| -0.6% | -$21.6K | ﹤0.01% | 1567 |
|
|
2021
Q3 | $3.54M | Sell |
179,625
-39,987
| -18% | -$837K | ﹤0.01% | 1566 |
|
|
2021
Q2 | $4.83M | Sell |
219,612
-3,832
| -2% | -$85.3K | 0.01% | 1446 |
|
|
2021
Q1 | $5.32M | Buy |
223,444
+5,534
| +3% | +$148K | 0.01% | 1371 |
|
|
2020
Q4 | $5.7M | Buy |
217,910
+63
| +0% | +$1.33K | 0.01% | 1282 |
|
|
2020
Q3 | $3.79M | Sell |
217,847
-22,385
| -9% | -$357K | 0.01% | 1324 |
|
|
2020
Q2 | $4.04M | Sell |
240,232
-13,891
| -5% | -$195K | 0.01% | 1331 |
|
|
2020
Q1 | $3.02M | Buy |
254,123
+2,100
| +0.8% | +$26K | 0.01% | 1323 |
|
|
2019
Q4 | $3.05M | Buy |
252,023
+19,240
| +8% | +$268K | 0.01% | 1556 |
|
|
2019
Q3 | $3.29M | Buy |
232,783
+179
| +0.1% | +$2.2K | 0.01% | 1428 |
|
|
2019
Q2 | $2.59M | Buy |
232,604
+4,416
| +2% | +$49.2K | ﹤0.01% | 1581 |
|
|
2019
Q1 | $2.68M | Sell |
228,188
-2,778
| -1% | -$34.5K | 0.01% | 1540 |
|
|
2018
Q4 | $3.09M | Buy |
230,966
+46,944
| +26% | +$620K | 0.01% | 1386 |
|
|
2018
Q3 | $2.58M | Buy |
184,022
+775
| +0.4% | +$10.8K | 0.01% | 1521 |
|
|
2018
Q2 | $2.88M | Buy |
183,247
+11,790
| +7% | +$205K | 0.01% | 1468 |
|
|
2018
Q1 | $2.82M | Buy |
171,457
+3,400
| +2% | +$63K | 0.01% | 1404 |
|
|
2017
Q4 | $3.04M | Buy |
168,057
+78,700
| +88% | +$1.43M | 0.01% | 1374 |
|
|
2017
Q3 | $1.73M | Buy |
89,357
+1,685
| +2% | +$25.1K | ﹤0.01% | 1700 |
|
|
2017
Q2 | $1.03M | Buy |
87,672
+15,494
| +21% | +$168K | ﹤0.01% | 1940 |
|
|
2017
Q1 | $791K | Buy |
72,178
+2,492
| +4% | +$21.9K | ﹤0.01% | 2031 |
|
|
2016
Q4 | $506K | Buy |
69,686
+9,684
| +16% | +$75.9K | ﹤0.01% | 2222 |
|
|
2016
Q3 | $390K | Buy |
60,002
+3,139
| +6% | +$18.3K | ﹤0.01% | 2347 |
|
|
2016
Q2 | $310K | Buy |
56,863
+8,272
| +17% | +$43K | ﹤0.01% | 2510 |
|
|
2016
Q1 | $227K | Sell |
48,591
-40
| -0.1% | -$156 | ﹤0.01% | 2674 |
|
|
2015
Q4 | $242K | Buy |
48,631
+4,855
| +11% | +$21.9K | ﹤0.01% | 2692 |
|
|
2015
Q3 | $165K | Buy |
43,776
+1,951
| +5% | +$9.9K | ﹤0.01% | 2853 |
|
|
2015
Q2 | $251K | Sell |
41,825
-1,650
| -4% | -$10.1K | ﹤0.01% | 2763 |
|
|
2015
Q1 | $243K | Buy |
43,475
+10,100
| +30% | +$36.6K | ﹤0.01% | 2729 |
|
|
2014
Q4 | $100K | Sell |
33,375
-8,510
| -20% | -$25.9K | ﹤0.01% | 2961 |
|
|
2014
Q3 | $112K | Hold |
41,885
| – | – | ﹤0.01% | 2913 |
|
|
2014
Q2 | $117K | Sell |
41,885
-1,620
| -4% | -$4.78K | ﹤0.01% | 2954 |
|
|
2014
Q1 | $190K | Sell |
43,505
-2,600
| -6% | -$9.09K | ﹤0.01% | 2787 |
|
|
2013
Q4 | $148K | Sell |
46,105
-200
| -0.4% | -$404 | ﹤0.01% | 2904 |
|
|
2013
Q3 | $74K | Sell |
46,305
-491
| -1% | -$866 | ﹤0.01% | 2955 |
|
|
2013
Q2 | $81K | Buy |
+46,796
| New | +$84.1K | ﹤0.01% | 3272 |
|
Other funds holding CORT
ISL
PA
RhumbLine Advisers's CORT Position: Q2 2026 in Review
RhumbLine Advisers reduced its Corcept Therapeutics (CORT) stake by 1.5% in Q2 2026, selling an estimated $177K and leaving 187,772 shares worth $16.3M. The position accounts for 0.01% of the portfolio, ranked #858.
RhumbLine Advisers first reported a position in CORT in Q2 2013 and has held it in 53 quarters since. The position peaked at $23M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.
- RhumbLine Advisers held 187,772 shares of Corcept Therapeutics worth $16.3M as of Q2 2026.
- RhumbLine Advisers sold 2,926 Corcept Therapeutics shares in Q2 2026, an estimated $177K.
- Corcept Therapeutics made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #858 holding.
- RhumbLine Advisers first reported a position in Corcept Therapeutics in Q2 2013 and has held it in 53 quarters since.
- RhumbLine Advisers's Corcept Therapeutics position peaked at $23M in Q1 2025.
- 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.